Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Stock Exchange VTX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolVTX:NOVN
Previous Symbol
CUSIPN/A
Phone+41-61-3241111
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable
Novartis (VTX:NOVN) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the VTX under the ticker symbol "NOVN."
What price target have analysts set for NOVN?
20 analysts have issued twelve-month target prices for Novartis' stock. Their forecasts range from CHF 79 to CHF 100. On average, they anticipate Novartis' share price to reach CHF 89.50 in the next year. This suggests a possible upside of 14.2% from the stock's current price. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
Press coverage about NOVN stock has trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
- Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
- Mr. Andrew Novak, VP & Chief Accounting Officer
What is Novartis' stock price today?
One share of NOVN stock can currently be purchased for approximately CHF 78.38.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.
MarketBeat Community Rating for Novartis (VTX NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
